Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Sel3.5

Selegilin – Forschung

Überwiegend Mechanismus / Beobachtung

12 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Selegilin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1996–2026 mit einer typischen Studiengröße von 903 Teilnehmenden.

Basierend auf 12 Studien · 1 Meta-Analyse · 4,723 Teilnehmende insgesamt

Konfidenz

Mittlere Konfidenz

Nach Outcome

Lifespan & aging (animal, mixed)Verlängert in einigen Tiermodellen Lebensdauer/Funktion (uneinheitlich); ein auf Healthspan ausgerichtetes Repurposing-Ziel, keine belegte Longevity-Intervention beim Menschen. · Nicht belegt
Überwiegend Mechanismus / Beobachtung6 Studien
Neuroprotection & cognition
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien

Aktives Forschungsgebiet

7 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025

199620112026

1Systematische Übersichtn=3,802 · very large study2026

Systematic review registration Registered in PROSPERO (CRD420251013028): https://www.crd.york.ac.uk/PROSPERO/view/CRD420251013028.

Shim SR, Jung YJ, Kwon KY, Rhee TG, Lee SM. · Frontiers in neurology (2026)

Treatment effects were expressed as standardized mean differences (SMDs) with 95% credible intervals (CrIs).
The combination of extended-release rasagiline and pramipexole (P2B001) showed the most significant improvement in global QoL (SMD = -4.16; 95% CrI: -7.24 to -1.05), followed by rasagiline monotherapy (SMD = -2.38; 95% CrI: -4.32 to -0.42).
Safinamide 100 mg significantly improved emotional well-being (SMD = -2.56; 95% CrI: -5.13 to -0.04).

Quelle ansehen

2Systematische Übersicht2025

While MAO-B inhibitors may support fatigue management, their precise role and optimal use require further investigation.

Galli S, Pacilio P, Bianchini E, Alborghetti M, De Carolis L, Lombardo P, Garramone F, Salvetti M, Rinaldi D. · Journal of clinical medicine (2025)

Rasagiline has been associated with reduced fatigue progression in early PD, with some studies showing significant improvements compared to placebo.
Studies indicate safinamide can significantly reduce fatigue levels.
Its ability to reduce glutamate release is particularly relevant, given the role of glutamate overactivity in PD-related fatigue.

Quelle ansehen

3Systematische Übersichtn=903 · large study2025

High-quality studies are needed.

Fornaro M, Caiazza C, Pistone L, Di Lorenzo C, Crincoli W, Pezone R, Tufano G, Oliva V, De Prisco M, Miola A, Iasevoli F, Vieta E, Solmi M, de Bartolomeis A. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2025)

Depressive symptom change (standardized mean difference/SMD), response, and all-cause discontinuation (acceptability) (risk ratio/RR) were co-primary outcomes; tolerability was the secondary outcome.
For efficacy (k = 16, N = 903, treatments=12), only phenelzine outperformed placebo (SMD=-1.31, 95 %C.I.=[-2.14;-0.49]).
Phenelzine, moclobemide, isocarboxazid, imipramine, selegiline, sertraline, and fluoxetine all outperformed nortriptyline (from SMD=-4.54, 95 %C.I.=[-8.02;-1.07] to SMD=-3.08, 95 %C.I.=[-5.42; -0.75]).

Quelle ansehen

4Systematische Übersicht2025

Further large-scale, methodologically rigorous studies are needed to confirm their clinical utility.

Bieś R, Krzystanek M, Górski M, Koźmin-Burzyńska A, Warchala A, Trędzbor B, Martyniak E, Fojcik J. · Pharmaceuticals (Basel, Switzerland) (2025)

Selegiline, particularly in transdermal form, reduced HAM-D scores by approximately 40% from baseline and by 25-30% relative to placebo.
Amantadine augmentation achieved ≥50% symptom improvement in 60-70% of treatment-resistant cases.
Bromocriptine yielded comparable response rates (~60%) to tricyclic antidepressants.

Quelle ansehen

5Systematische Übersicht2024

As for safety, safinamide combination with dopaminergic treatment had lower risk of incurring any adverse events.

Wang Y, Wang Z. · European neurology (2024)

For safety outcomes, safinamide combination with dopaminergic treatment had lower risk of incurring any adverse events (risk ratio = 0.1, 95% CI = 0.01-0.2), and no statistical difference in incidence of adverse events was observed among other MAO-B inhibitor regimes and placebo.
The surface under the cumulative ranking results showed that rasagiline ranked first in improving UPDRS II and UPDRS III, respectively.
Conclusion Rasagiline, selegiline, safinamide, and zonisamide were effective compared to placebo in the treatment of early PD, but rasagiline was the most effective drug.

Quelle ansehen

6Systematische Übersicht2024

The purpose of this review is to investigate the preclinical and clinical pharmacology of selegiline, rasagiline, and safinamide in Parkinson's disease and beyond, focusing on possible future therapeutic applications.

Alborghetti M, Bianchini E, De Carolis L, Galli S, Pontieri FE, Rinaldi D. · Neural regeneration research (2024)

Besides, safinamide may interfere with neurodegenerative mechanisms, counteracting excessive glutamate overdrive in basal ganglia motor circuit and reducing death from excitotoxicity.
Due to the dual mechanism of action, the new generation of type-B monoamine oxidase inhibitors, including safinamide, is gaining interest in other neurological pathologies, and many supporting preclinical studies are now available.
The potential fields of application concern epilepsy, Duchenne muscular dystrophy, multiple sclerosis, and above all, ischemic brain injury.

Quelle ansehen

7Meta-Analyse2025

A 2025 meta-analysis of 22 longevity experiments concluded that l-deprenyl reproducibly extends lifespan across mammalian species.

Bene · Ageing research reviews (2025)

Meta-analysis of 22 l-deprenyl (selegiline) longevity experiments across mammalian species
Concluded a reproducible lifespan-extension effect — strengthening the previously mixed individual-study picture
The most systematically-analyzed animal lifespan evidence of any geroprotector in this collection

Quelle ansehen

8Tierstudien=18 · very small study1996

Long-term low-dose (-)deprenyl extended lifespan in ovariectomized female rats compared with saline controls.

Dalló, Köles · Acta physiologica Hungarica (1996)

Female rats given low-dose deprenyl outlived saline controls (which 'decayed' by ~15 months)
Suggested a lifespan and copulatory-activity benefit in aged females
Part of the historical deprenyl-longevity literature

9Übersicht1998

The effects of deprenyl on longevity and antioxidant defenses are reviewed across animal species, with mixed lifespan findings.

Kitani, Kanai, Ivy, Carrillo · Annals of the New York Academy of Sciences (1998)

Review of deprenyl's longevity and antioxidant-enzyme effects across species
Notes inconsistent lifespan results between laboratories and species
Frames antioxidant-enzyme induction as a proposed mechanism

Quelle ansehen

10Tierstudie1997

Long-term l-deprenyl in male Fischer 344 rats was assessed for effects on longevity and sensorimotor/learning function.

Bickford, Adams, Boyson, Curella, Gerhardt, Heron · Neurobiology of aging (1997)

Male F344 rats given deprenyl in drinking water from 54 weeks, evaluated behaviorally
Assessed motor-learning and sensorimotor outcomes with aging
Male-rat lifespan effects were more modest/mixed than the female data

Quelle ansehen

11Übersicht2002

Propargylamines such as deprenyl are reviewed as candidate pharmacological interventions in aging and age-associated disorders.

Kitani, Minami, Yamamoto, Kanai, Ivy, Carrillo · Annals of the New York Academy of Sciences (2002)

Review of propargylamine (deprenyl/rasagiline) interventions in aging
Covers neuroprotective and anti-apoptotic mechanisms
Positions deprenyl among candidate geroprotective drugs

Quelle ansehen

12Übersicht2002

Neuroprotection by propargylamines in Parkinson's disease involves suppression of apoptosis and induction of pro-survival factors.

Maruyama, Akao, Carrillo, Kitani, Youdium, Naoi · Neurotoxicology and teratology (2002)

Mechanistic review of propargylamine neuroprotection in Parkinson's
Describes anti-apoptotic and pro-survival signaling
Supports the neuroprotection rationale behind longevity interest

Quelle ansehen

In der Forschungsbibliothek ansehen

Selegilin – Forschung

Überwiegend Mechanismus / Beobachtung

Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis

The Role of MAO-B Inhibitors in Fatigue in Parkinson's Disease: A Narrative Review

Pharmacological treatments for atypical depression: A systematic review and network meta-analysis of randomized controlled trials

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review

Effects and Safety of Monoamine Oxidase-B Inhibitors for Early Parkinson's Disease: A Network Meta-Analysis

Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings

L-deprenyl extends lifespan across mammalian species: A meta-analysis of 22 longevity experiments.

Longevity treatment with (-)deprenyl in female rats: effect on copulatory activity and lifespan.

Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models.

Long-term treatment of male F344 rats with deprenyl: assessment of effects on longevity, behavior, and brain function.

Pharmacological interventions in aging and age-associated disorders: potentials of propargylamines for human use.

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.